EUCTR2005-001360-31-IT进行中（未招募）不适用
A multicenter, randomised, double- blind, between-patient, dose finding study to assess the safety, tolerability and efficacy of three different dosages (500, 1000 and 2000 mcg/g) of ABIO 12/01 gel, in comparison to an open active treatment, after a five-day vaginal administration to females with a confirmed clinical diagnosis of vulvovaginal candidiasis.
ABIOGEN PHARMA0 个研究点目标入组 200 人开始时间: 2005年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyParkinson 's Disease early stageMedDRA version: 8.1Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2006-000678-57-EESolvay pharmaceuticals330
进行中（未招募）
1 期
A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyEUCTR2006-000678-57-FRSolvay pharmaceuticals330
进行中（未招募）
不适用
A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyParkinson 's Disease early stageMedDRA version: 8.1Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2006-000678-57-PTSolvay pharmaceuticals B.V.330
进行中（未招募）
不适用
A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyParkinson 's Disease early stageMedDRA version: 8.1Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2006-000678-57-NLSolvay pharmaceuticals330
进行中（未招募）
不适用
A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyParkinson 's Disease early stageMedDRA version: 8.1Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2006-000678-57-LTSolvay pharmaceuticals330